Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-d]pyrimidine derivatives as new EGFR inhibitors

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• WHO. Cancer, Overview. [accessed 2022 Oct 1]. https://www.who.int/health-topics/cancer#tab=tab_1.
   Google Scholar
• Badran MM, Abouzid KM, Hussein MHM. Synthesis of certain substituted quinoxalines as antimicrobial agents (part II). Arch Pharm Res. 2003;26(2):107–113.
   PubMed Web of Science ®Google Scholar
• WHO. Cancer, Key facts. [accessed 2023 Mar 1]. https://www.who.int/news-room/fact-sheets/detail/cancer.
   Google Scholar
• Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65–72.
   PubMed Web of Science ®Google Scholar
• Krauss G, Schönbrunner N, Cooper J. Biochemistry of signal transduction and regulation. Weinheim (Germany): Wiley Online Library; 2003. Vol. 3.
   Google Scholar
• Nguyen K-SH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281–289.
   PubMed Web of Science ®Google Scholar
• Grant S. Therapeutic protein kinase inhibitors. Cell Mol Life Sci. 2009;66(7):1163–1177.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
   PubMed Web of Science ®Google Scholar
• Huang S-M, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17(3):259–269.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JMW, Harper ME. egfR and cancer prognosis. Eur J Cancer. 2001;37:9–15.
   PubMed Web of Science ®Google Scholar
• Zhang H-Q, Gong F-H, Ye J-Q, Zhang C, Yue X-H, Li C-G, Xu Y-G, Sun L-P. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. Eur J Med Chem. 2017;125:245–254.
   PubMed Web of Science ®Google Scholar
• Song Z, Huang S, Yu H, Jiang Y, Wang C, Meng Q, Shu X, Sun H, Liu K, Li Y, et al. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem. 2017;133:329–339.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Xu H, Li X, Zhao L, Wang W, Li B, Zhang X. 6, 7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur J Med Chem. 2018;147:77–89.
   PubMed Web of Science ®Google Scholar
• Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003;12(8):1395–1401.
   PubMed Web of Science ®Google Scholar
• Ou S-HI. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012;83(3):407–421.
   PubMed Web of Science ®Google Scholar
• Walter AO, Sjin RTT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013;3(12):1404–1415.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non–small-cell lung cancer. J Clin Oncol. 2010;28(18):3076–3083.
   PubMed Web of Science ®Google Scholar
• Kim Y, Ko J, Cui ZYun, Abolhoda A, Ahn JS, Ou S-H, Ahn M-J, Park K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther. 2012;11(3):784–791.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol. 2014;9(6):1230–1241.
   PubMed Web of Science ®Google Scholar
• Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U, Traxler P. Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des. 1995;9(6):465–472.
   PubMed Web of Science ®Google Scholar
• Gandin V, Ferrarese A, Dalla Via M, Marzano C, Chilin A, Marzaro G. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci Rep. 2015;5:16750.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358–364.
   PubMed Web of Science ®Google Scholar
• Elrazaz EZ, Serya RAT, Ismail NSM, Abou El Ella DA, Abouzid KAM. Thieno [2, 3-d] pyrimidine based derivatives as kinase inhibitors and anticancer agents. Future J Pharm Sci. 2015;1(2):33–41.
   Google Scholar
• Yang C-R, Peng B, Cao S-L, Ren T-T, Jiang W, Wang F-C, Li Y-S, Wang G, Li Z, Xu S, et al. Synthesis, cytotoxic evaluation and target identification of thieno [2, 3-d] pyrimidine derivatives with a dithiocarbamate side chain at C2 position. Eur J Med Chem. 2018;154:324–340.
   PubMed Web of Science ®Google Scholar
• Rashad A, Ali M. Synthesis and antiviral screening of some thieno [2, 3-d] pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids. 2006;25(1):17–28.
   PubMed Web of Science ®Google Scholar
• Kotaiah Y, Harikrishna N, Nagaraju K, Venkata Rao C. Synthesis and antioxidant activity of 1, 3, 4-oxadiazole tagged thieno [2, 3-d] pyrimidine derivatives. Eur J Med Chem. 2012;58:340–345.
   PubMed Web of Science ®Google Scholar
• Vega S, Alonso J, Diaz JA, Junquera F, Perez C, Darias V, Bravo L, Abdallah S. Thiophene isosteres: synthesis and biological evaluation of 3-substituted derivatives of 4-phenyl-2-thioxo-benzo [4, 5] thieno [2, 3-d] pyrimidine. Eur J Med Chem . 1991;26(3):323–329.
   Web of Science ®Google Scholar
• El-Gazzar A-R, Hussein H, Hafez H. Synthesis and biological evaluation of thieno [2, 3-d] pyrimidine derivatives for anti-inflammatory, analgesic and ulcerogenic activity. Acta Pharm. 2007;57(4):395–411.
   PubMedGoogle Scholar
• Vlasov SV, Osolodchenko TP, Kovalenko SM, Chernykh VP. Synthesis and the antimicrobial activity of 1-alkyl-5-methyl-3-phenyl-6-(5-phenyl-1, 3, 4-oxadiazol-2-yl) thieno [2, 3-d] pyrimidine-2, 4 (1H, 3H)-diones. J Org Pharm Chem. 2015;13(1(49)):20–24.
   Google Scholar
• Ali EMH, Abdel-Maksoud MS, Oh C-H. [2, 3-d] pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. Bioorg Med Chem. 2019;27(7):1159–1194.
   PubMed Web of Science ®Google Scholar
• Bugge S, Kaspersen SJ, Larsen S, Nonstad U, Bjørkøy G, Sundby E, Hoff BH. Structure–activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. Eur J Med Chem. 2014;75:354–374.
   PubMed Web of Science ®Google Scholar
• Gaber AA, Bayoumi AH, El-Morsy AM, Sherbiny FF, Mehany ABM, Eissa IH. Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg Chem. 2018;80:375–395.
   PubMed Web of Science ®Google Scholar
• Elmetwally SA, Saied KF, Eissa IH, Elkaeed EB. Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem. 2019;88:102944.
   PubMed Web of Science ®Google Scholar
• Nasser AA, Eissa IH, Oun MR, El-Zahabi MA, Taghour MS, Belal A, Saleh AM, Mehany ABM, Luesch H, Mostafa AE, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org Biomol Chem. 2020;18(38):7608–7634.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Xie L, Bourne PE. Structural insights into characterizing binding sites in epidermal growth factor receptor kinase mutants. J Chem Inf Model. 2019;59(1):453–462.
   PubMed Web of Science ®Google Scholar
• Kandeel MM, Mounir AA, Refaat HM, Kassab AE. Synthesis of thieno [2, 3-d] pyrimidines, thieno [2, 3-d] triazinones and thieno [2, 3-e] diazepinones of anticipated anti-cancer activity. J Chem Res. 2012;36(2):105–110.
   Google Scholar
• Tormyshev V, Trukhin D, Rogozhnikova O, Mikhalina T, Troitskaya T, Flinn A. Aryl alkyl ketones in a one-pot Gewald synthesis of 2-aminothiophenes. Synlett. 2006;2006(16):2559–2564.
   Google Scholar
• El‐Adl K, Ibrahim M‐K, Khedr F, Abulkhair HS, Eissa IH. N‐Substituted‐4‐phenylphthalazin‐1‐amine‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluation studies. Arch Pharm. 2021;354(3):2000219.
   Web of Science ®Google Scholar
• Abdelhaleem EF, Abdelhameid MK, Kassab AE, Kandeel MM. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Eur J Med Chem. 2018;143:1807–1825.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55–63.
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271–277.
   PubMed Web of Science ®Google Scholar
• Thabrew MI, Hughes RD, Mcfarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol. 1997;49(11):1132–1135.
   PubMed Web of Science ®Google Scholar
• Li P, Zhang Q, Torossian A, Li Z-b, Xu W-c, Lu B, Fu S. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):e391–e397.
   PubMed Web of Science ®Google Scholar
• Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70(11):1568–1578.
   PubMed Web of Science ®Google Scholar
• Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells. Mol Cancer Ther. 2006;5(5):1154–1165.
   PubMed Web of Science ®Google Scholar
• Jia Y, Quinn CM, Gagnon AI, Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem. 2006;356(2):273–281.
   PubMed Web of Science ®Google Scholar
• Pietenpol J, Stewart Z. Cell cycle checkpoint signaling:: cell cycle arrest versus apoptosis. Toxicology. 2002;181-182:475–481.
   PubMed Web of Science ®Google Scholar
• Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J. 2012;448(3):417–423.
   PubMed Web of Science ®Google Scholar
• Sogabe S, Kawakita Y, Igaki S, Iwata H, Miki H, Cary DR, Takagi T, Takagi S, Ohta Y, Ishikawa T, et al. Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med Chem Lett. 2013;4(2):201–205.
   PubMed Web of Science ®Google Scholar
• Ferreira LL, Andricopulo A. ADMET modeling approaches in drug discovery. Drug Discov Today. 2019;24(5):1157–1165.
   PubMed Web of Science ®Google Scholar
• Dearden JC. In silico prediction of drug toxicity. J Comput Aided Mol Des. 2003;17(2-4):119–127.
   PubMed Web of Science ®Google Scholar
• Kruhlak NL, Benz RD, Zhou H, Colatsky TJ. (Q) SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther. 2012;91(3):529–534.
   PubMed Web of Science ®Google Scholar
• Golub AG, Bdzhola VG, Briukhovetska NV, Balanda AO, Kukharenko OP, Kotey IM, Ostrynska OV, Yarmoluk SM. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem. 2011;46(3):870–876.
   PubMed Web of Science ®Google Scholar
• Abbas SE, Abdel Gawad NM, George RF, Akar YA. Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives. Eur J Med Chem. 2013;65:195–204.
   PubMed Web of Science ®Google Scholar
• Al-Rashood ST, Hamed AR, Hassan GS, Alkahtani HM, Almehizia AA, Alharbi A, Al-Sanea MM, Eldehna WM. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J Enzyme Inhib Med Chem. 2020;35(1):831–839.
   PubMed Web of Science ®Google Scholar
• Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, et al. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem. 2022;37(1):403–416.
   Web of Science ®Google Scholar
• Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci. 2000;113(5):753–757.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Hassan GS, Al-Rashood ST, Al-Warhi T, Altyar AE, Alkahtani HM, Almehizia AA, Abdel-Aziz HA. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem. 2019;34(1):322–332.
   PubMed Web of Science ®Google Scholar
• Lo KK-W, Lee TK-M, Lau JS-Y, Poon W-L, Cheng S-H. Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg Chem. 2008;47(1):200–208.
   PubMed Web of Science ®Google Scholar
• Sabt A, Abdelhafez OM, El-Haggar RS, Madkour HMF, Eldehna WM, El-Khrisy EE-DAM, Abdel-Rahman MA, Rashed LA. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem. 2018;33(1):1095–1107.
   PubMed Web of Science ®Google Scholar
• Balah A, Ezzat O, Akool E-S. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-β/Smad signaling pathway in rat liver. Int Immunopharmacol. 2018;65:493–502.
   PubMed Web of Science ®Google Scholar
• Aborehab NM, Elnagar MR, Waly NE. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF‐7 human breast cancer cell line. J Biochem Mol Toxicol. 2021;35(2):e22638.
   PubMed Web of Science ®Google Scholar
• Elnagar MR, Walls AB, Helal GK, Hamada FM, Thomsen MS, Jensen AA. Functional characterization of α7 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Eur J Pharmacol. 2018;826:106–113.
   PubMed Web of Science ®Google Scholar
• Elkaeed EB, Eissa IH, Elkady H, Abdelalim A, Alqaisi AM, Alsfouk AA, Elwan A, Metwaly AM. A multistage in silico study of natural potential inhibitors targeting SARS-CoV-2 main protease. Int J Mol Sci. 2022;23(15):8407.
   PubMed Web of Science ®Google Scholar
• Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML, El Hassab MA, Abou-Seri SM, Metwaly AM. Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. Int J Mol Sci. 2022;23(13):6912.
   PubMed Web of Science ®Google Scholar
• Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk BA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: in vitro anticancer and VEGFR-2 inhibitory effects. Molecules. 2022;27(14):4606.
   PubMed Web of Science ®Google Scholar
• Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, Eissa IH, et al. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem. 2022;37(1):1903–1917.
   PubMed Web of Science ®Google Scholar
• Yousef RG, Sakr HM, Eissa IH, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, El-Adl K, et al. New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J Chem. 2021;45(36):16949–16964.
   Web of Science ®Google Scholar